Sign In
Buy QGEN
$36.45
+0.760 (+2.13%)
At Close: Jun 03, 2026
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
10:56am, Friday, 16'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Here's Why Qiagen (QGEN) is a Strong Value Stock
10:46am, Thursday, 15'th May 2025
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Qiagen Beats Earnings, But Its Expensive Valuation Caps Upside Potential
07:30am, Thursday, 15'th May 2025
QGEN has a relatively well-diversified portfolio across four segments on Sample Technologies, PCR/NA Amplification, Genomics/NGS, and Diagnostic Solutions. Their QIAstat-Dx's multiplex syndromic panel
QIAGEN Stock Gains Following the Acquisition of Genoox
08:10am, Tuesday, 13'th May 2025
QGEN inks an agreement to acquire Genoox for $70 million in cash. The acquisition expands QIAGEN's QDI portfolio.
Qiagen N.V. (QGEN) Q1 2025 Earnings Call Transcript
02:48pm, Thursday, 08'th May 2025
Qiagen N.V. (NYSE:QGEN ) Q1 2025 Earnings Conference Call May 8, 2025 9:00 AM ET Company Participants John Gilardi - Vice President, Head of Corporate Communications & Investor Relations Thierry Berna
QGEN Q1 Earnings and Revenues Top, Operating Margin Expands, Stock Up
07:55am, Thursday, 08'th May 2025
QGEN's quarterly performance benefits from a resilient portfolio in the first quarter of 2025.
Here's What Key Metrics Tell Us About Qiagen (QGEN) Q1 Earnings
08:30pm, Wednesday, 07'th May 2025
While the top- and bottom-line numbers for Qiagen (QGEN) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to
Qiagen (QGEN) Q1 Earnings and Revenues Surpass Estimates
07:20pm, Wednesday, 07'th May 2025
Qiagen (QGEN) came out with quarterly earnings of $0.55 per share, beating the Zacks Consensus Estimate of $0.50 per share. This compares to earnings of $0.47 per share a year ago.
QIAGEN announces plans for transition in leadership of Supervisory Board
04:20pm, Wednesday, 07'th May 2025
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board intends to elect Stephen H. Rusckowski to
QIAGEN to Propose Initiation of Annual Cash Dividend for Shareholder Approval at Annual General Meeting
08:45am, Wednesday, 07'th May 2025
VENLO, the Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its Supervisory Board will propose the initiation of an annual c
Stay Ahead of the Game With Qiagen (QGEN) Q1 Earnings: Wall Street's Insights on Key Metrics
10:20am, Tuesday, 06'th May 2025
Get a deeper insight into the potential performance of Qiagen (QGEN) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some
Activist Fivespan has a stake in Qiagen. Here are 3 levers to boost the company's growth and improve value
10:47am, Saturday, 03'rd May 2025
Management at Qiagen has done the hard things right, but there is now an opportunity for the company to grow faster and in a more focused way.
QGEN or RGEN: Which Is the Better Value Stock Right Now?
12:41pm, Friday, 02'nd May 2025
Investors interested in stocks from the Medical - Biomedical and Genetics sector have probably already heard of Qiagen (QGEN) and Repligen (RGEN). But which of these two stocks is more attractive to v
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
11:06am, Wednesday, 30'th Apr 2025
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
QIAGEN Expands Its Digital PCR Portfolio With New Lentivirus Solutions to Strengthen Cell and Gene Therapy Quality Control
04:05pm, Tuesday, 29'th Apr 2025
VENLO, the Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR (dPC
